Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Oestrogen therapy alone vs placebo

Rate of survival: overall survival · women previously treated for endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Hormone replacement therapy for women previously treated for endometrial cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs placebo

Progression‐free survival (PSF) · women previously treated for endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Hormone replacement therapy for women previously treated for endometrial cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall survival (OS) · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Adverse events, · stage III cutaneous melanoma

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 1 [0.75, 1.34]
1 study · 20 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall response rate (ORR), · stage III cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Time to recurrence ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Quality of life ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Death Number of deaths over 36 months · stage III and IV cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Moderate

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Adverse events, · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 8.73 [1.29, 59]
1 study · 23 participants
Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 2.91 [1.02, 8.27]
1 study · 23 participants
Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Time to recurrence · stage III and IV cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Quality of life ‐ not measured · stage III and IV cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Overall survival (OS) · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Adverse events, · stage III cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Overall response rate (ORR), · stage III cutaneous melanoma

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in overall response rate (ORR), compared with neoadjuvant immunotherapy (sequential treatment with ipilimumab then… (low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 1.42 [0.87, 2.32]
1 study · 86 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Time to response ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Quality of life ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cognitive behavioural therapy plus adjunctive physical activity vs cognitive behavioural therapy

Reduction in physical signs (overall physical impact) As measured by PMDRS, total score (lower is better) · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Cognitive behavioural therapy plus adjunctive physical activity vs cognitive behavioural therapy

Level of functioning · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cognitive behavioural therapy plus adjunctive physical activity vs cognitive behavioural therapy

Quality of life · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found